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Abstract
Purpose Vitamin D deficiency has been reported as a key factor in the development of infectious diseases such as respiratory 
tract infections and inflammatory processes like acute respiratory distress syndrome. However, the impact of vitamin D on 
the severity and outcome of COVID-19 is still not fully known. Herein, we aimed to evaluate the prognostic role of serum 
vitamin D concentration on the extent of lung involvement and final outcome in patients with COVID-19.
Methods Seventy-three subjects with confirmed diagnosis of COVID-19 were investigated in this study. The patients had 
been admitted to our academic hospital from February 28, 2020 to April 19, 2020. Demographic and clinical data, serum 
25(OH)D levels, and findings of initial chest computed tomography were recorded. Linear and binary logistic regression, 
cox regression and ROC curve tests were used for statistical analysis.
Results The mean age of patients was 55.18 ± 14.98 years old; 46.4% were male. Mean serum 25(OH)D concentration 
was significantly lower in the deceased (13.83 ± 12.53 ng/ mL compared with discharged patients (38.41 ± 18.51 ng/mL) 
(P < 0.001). Higher levels of 25(OH)D were associated with significantly less extent of total lung involvement (β = − 0.10, 
P = 0.004). In addition, vitamin D deficiency [25(OH) D < 25 ng/mL] was associated with a significant increase in the risk 
of mortality (hazard ratio = 4.15, P = 0.04).
Conclusion This study suggests that serum vitamin D status might provide useful information regarding the clinical course, 
extent of lung involvement and outcome of patients with COVID-19. However, further studies with larger sample size are 
needed to confirm these findings.
Keywords COVID-19 · Computed tomography · Vitamin D · Outcome
Introduction
Coronavirus disease 2019 (COVID-19) is a novel, highly 
contagious viral infection that has affected many healthcare 
systems across the world in the recent months. It is caused by 
the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) and was initially identified in Wuhan, Hubei, China, 
in late 2019 [1]. The most common symptoms of COVID-
19 are cough, fatigue, fever, shortness of breath and sore 
throat [2]. Nevertheless, the spectrum of disease severity 
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ranges from asymptomatic illness to critical respiratory 
distress and death [3]. Based on previous reports, elderly 
patients (older than 60 years) and those with pre-existing 
comorbidities such as diabetes, hypertension, cardiovascular 
disease, chronic respiratory disease, and cancer are more 
likely to suffer from severe disease [4]. Moreover, it is has 
been shown that different clinical and laboratory factors can 
also impact COVID-19 disease course and outcome [5, 6]. 
Hence, it is essential to identify other factors that might pos-
sibly make patients prone to more severe form of disease.
Vitamin D is an immunomodulatory hormone that regu-
lates both innate and adaptive immune function [7]. Vitamin 
D deficiency plays an important role in the development and 
persistence of inflammation, which is a key feature in the 
pathogenesis of acute respiratory distress syndrome (ARDS) 
[8, 9]. According to previous studies, higher serum con-
centrations of 25-hydroxyvitamin D (25[OH]D) have been 
related with reduced risk of influenza progression during 
winter [10]. 25(OH)D concentration has also been shown 
to play a possible role in several infectious diseases such 
as respiratory tract infections (RTI), tuberculosis (TB), 
human immunodeficiency virus infection (HIV) and sepsis 
[11]. In addition, vitamin D deficiency is associated with an 
increased risk of all-cause mortality in the general popula-
tion [12].
Vitamin D employs different mechanisms in reducing 
the risk of viral infection and mortality. Several of these 
mechanisms include maintenance of cell junctions and gap 
junctions, strengthening of cellular immunity by diminish-
ing the cytokine storm (via modulation of interferon γ and 
tumor necrosis factor-α secretion) and regulating adaptive 
immunity through inhibiting type 1 T helper cell responses 
and stimulating T cell induction [10, 13]. Although the anti-
viral, immunomodulatory and anti-inflammatory effects of 
Vitamin D have been exhibited in different studies, its effect 
on COVID-19 has not been studied thoroughly [14].
On the other hand, chest computed tomography (CT) 
plays an important role in the diagnosis of COVID-19, dem-
onstrating a high sensitivity of approximately 98% [15]. In 
addition, chest CT is considered a useful tool for evaluating 
the clinical severity of COVID-19 and guiding clinicians for 
better management of the infection [16].
Bearing this in mind, this study aimed to evaluate the 
possible existence of an interplay between serum 25(OH)D 
concentrations and the extent of lung involvement and clini-
cal outcome in patients with COVID-19. We particularly 
focus on Vitamin D deficient state and the risk of developing 
poor clinical outcomes in such patients.
Methods
Patient population
In this retrospective study, the medical records of 73 con-
firmed cases of COVID-19 who had been admitted to our 
academic hospital between February 28, 2020 and April 19, 
2020 were reviewed. Diagnosis of COVID-19 was based 
on the interim guidelines of the World Health Organization 
(WHO) and also national diagnosis and treatment guide-
lines of COVID-19. Cases with a time interval of more than 
three days between the performance of initial chest CT and 
measurement of serum 25(OH) level were excluded. Also, 
patients with negative RT-PCR result were not included in 
our study.
Data collection
Patients’ demographic data and past medical history includ-
ing the presence of hypertension, diabetes, ischemic heart 
disease, asthma, chronic lung disease, chronic liver disease, 
chronic kidney disease [estimated glomerular filtration rate 
(GFR) based on the Epidemiology Collaboration Equation 
(CKD- EPI) below 60 cc/min] and immunocompromised 
conditions were recorded. Comorbidity was defined as hav-
ing any of the aforementioned conditions.
Patients’ presenting symptoms including fever, cough, 
sore throat, dyspnea, chilling, headache, myalgia and gas-
trointestinal symptoms were collected from medical docu-
ments. Also, vital signs (pulse rate, blood pressure, respira-
tory rate, body temperature, and oxygen saturation on room 
air) were recorded for each patient. Finally, patients’ final 
disease outcome (death vs discharge) was also collected.
The study protocol was approved by ethics committee of 
Shahid Beheshti University of Medical Sciences (IR.SBMU.
MSP.REC.1399.040). Written consents were obtained from 
all participants.
Laboratory procedures
Serum calcium was assessed with photometric analysis 
by the Hitachi 747 autoanalyzer (Hitachi, Tokyo, Japan) 
at 37  °C with Arsenazo III, 200 μmol/L in 50 mmol/L 
1,4-piperazinediethanesulfonic acid (PIPES). Colorimet-
ric analysis was used to assess serum phosphorus with the 
same device, based on the phosphomolybdic acid, which is 
then reduced to molybdenum blue. Also, serum magnesium 
was measured with a colorimetric method based on xylidyl 
blue reaction. Magnesium ions in alkaline media react with 
xylidyl blue and produce an estimated 520 nm wave length. 
Measurement of 25(OH)D serum concentration was carried 
out with Roche Diagnostics “Vitamin D Total”, cobas e411 
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immunoassay analyzer. All laboratory examinations had 
been performed at admission. Nasopharynx samples were 
obtained from clinically suspected patients for evaluation 
by real-time reverse transcriptase polymerase chain reaction 
(RT-PCR) for SARS-COV-2 [DaAn Gene Co., Ltd. Sun Yat-
Sen University, SARS-CoV-2 Virus Detection Diagnostic 
Kit (RT-PCR Method].
Imaging studies
All patients had undergone non-contrast lung CT scan uti-
lizing a low dose protocol at admission. All CT scans were 
obtained with a 64-slice scanner (Siemens sensation; Sie-
mens Healthineers, Erlangen, Germany). The procedures 
were done in supine position during end-inspiration without 
contrast medium injection. The scanning parameters were as 
follows: gantry rotation time of 0.5 s, 0.625 mm × 64-detec-
tor array, pitch of 1.4, table speed of 45.2 mm/rotation, 20 
mAs, 120 kVp, and a 300 × 300 matrix. CARE Dose4D; 
CARE kV scanning parameters were off. One millimeter 
slice thickness and 1 mm reconstruction intervals were used 
for the purpose of reconstruction (sagittal and coronal). Eth-
anol and didecyldimethyl ammonium chloride were used for 
the disinfection of imaging facilities and passive air ventila-
tion was also performed in our radiology department.
Chest CT images were interpreted by two expert radi-
ologists with 9 and 18 years of experience, independently. 
The patterns of involvement were categorized as ground-
glass opacity (GGO), consolidation, reticular or mixed. 
The distribution of lung lesions (peripheral, central or 
both), and the predominant zonal involvement (upper, mid 
or lower) were also noted. The extent of the lung involve-
ment was assessed using the following scoring system: 0: no 
involvement, 1: < 25%, 2: 26–50%, 3: 51–75% and 4: > 75% 
[16]. The scores for each specific zone of both lungs were 
summed up to calculate the bilateral zonal score and the total 
involvement score was calculated by summation of all of 
the zonal scores (maximum score: 24). Other imaging fea-
tures including airway thickening, crazy paving, reverse halo 
sign, dilated vessels, airway dilatation, air-bronchogram, and 
lymphadenopathy (defined as a lymph node with a short 
axis > 10 mm) and pleural or pericardial effusions were also 
assessed. Lung zone involvement was classified based on 
three zones as follows: the upper zone, which was above 
the carina, the middle zone, defined as the area between 
the carina and inferior pulmonary vein, and the lower zone, 
defined as the region below the pulmonary vein [17].
Statistical analysis
Continuous variables are reported as mean ± SD for nor-
mally distributed data and median (Quartile 1–Quartile 
3) for skewed continuous data. Categorical variables are 
reported as frequency (percentage). Independent sample T 
test, Mann–Whitney U test, and chi-square test with exact P 
value were applied to compare continuous and categorical 
data between deceased and discharged patients. Normality 
assumption was tested using Shapiro–Wilk test.
Multivariate linear regression analysis was used for evalu-
ating the association between serum 25(OH)D levels and 
lung involvement score of the three zones (upper, middle 
and lower zones) as well as the total lung involvement score. 
Lung involvement scores were simultaneously entered in the 
multivariate analysis and were considered as a matrix of 
dependent variables. The assumptions of errors, variance 
consistency and normality of residuals were checked in 
regression models and, if applicable, the appropriate trans-
formation was performed to meet the mentioned criteria. 
ROC (receiver operating characteristic) curve analysis was 
conducted to determine the predictive ability of 25(OH)D 
in distinguishing final disease outcome (death vs discharge). 
The optimal cutoff point of 25(OH)D and its sensitivity and 
specificity was also calculated.
Binary logistic regression model was applied to deter-
mine the relationship between 25 (OH)D deficiency and final 
outcome (death vs discharged); odds ratio (OR) and 95% 
confidence interval were also reported to show the inten-
sity and direction of the relationship. Finally, considering 
“death" as event and length of hospitalization as “event 
time”, survival and proportional hazards cox regression 
analyses were performed to evaluate the effect of 25(OH)D 
deficiency on the hazard rate (HR) of death in patients with 
COVID-19. The assumption of proportionality of hazards in 
cox survival models was checked by Schoenfeld residues and 
log minus log functions, which are reported in Fig. 1. All 
statistical analysis was performed by STATA 14 and SPSS 
24 software. P < 0.05 was considered statistically significant.
Results
Patients’ demographic and clinical characteristics 
and imaging findings
Overall, 73 patients with confirmed COVID-19 were 
included in this study. The mean ± SD age of patients 
was 55.18 ± 14.98 years old; 29 (39.7%) were older than 
60 years. Approximately 64% of patients were male. Forty-
two patients (57.5%) reported at least one underlying comor-
bidity. The median duration of hospitalization was 10 days 
(range: 1–36) and 12 patients (16.4%) had eventually expe-
rienced COVID-19 related death.
Table 1 shows the baseline characteristics of patients in 
the discharged and deceased groups. Among investigated 
variables, age, gender, lung involvement pattern and lesion 
distribution did not differ significantly between the two study 
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groups (P > 0.05). Zonal lung involvement scores (upper, 
middle and lower zone) as well as the total lung involve-
ment score were significantly higher in the deceased group 
(P < 0.01).
None of the presenting signs and symptoms differed sig-
nificantly between the two groups (P > 0.05). Among CT 
imaging findings, dilated vessel (60.7% vs 100%, P = 0.006) 
and air bronchogram (23.0% vs 58.3%, P = 0.007) were more 
likely to be seen in the deceased compared with the dis-
charged patients. Also, the mean concentration of serum 
25(OH)D was significantly lower in patients who died 
(13.83 ± 12.53 ng/ mL) in comparison with the survivors 
(38.41 ± 18.51 ng/ mL) (P < 0.001).
Association between serum vitamin D level and lung 
involvement scores
The association between 25(OH)D concentration and lung 
involvement scores is shown in Table 2. As demonstrated by 
the results of multivariate linear regression analysis, a higher 
25(OH)D concentration was significantly associated with 
less extent of lung involvement (P < 0.01). Also, accord-
ing to adjusted multivariate regression analysis, higher 
25(OH)D levels were significantly associated with a lower 
amount of upper (β = − 0.03, P = 0.003), middle (β = − 0.03, 
P = 0.005), lower (β = − 0.04, P = 0.01) and total (β = − 0.10, 
P = 0.004) lung involvement.
By defining severe lung involvement as total lung involve-
ment score > 12, the relationship between 25(OH)D concen-
tration and extent of lung involvement was assessed using 
logistic regression. The results of this analysis showed that 
one unit increase in the 25(OH)D level leads to four percent 
reduction in the odds of developing severe lung involve-
ment (OR = 0.96, 95% CI 0.93–0.98, P = 0.04). The effect 
of potential confounders including sex, age and comorbidity 
status was adjusted in this evaluation. Figure 2 shows the 
extent of lung involvement in the CT images of two patients 
with different levels of 25(OH)D.
Optimal cut‑off value of vitamin D for predicting 
final outcome (death vs discharge)
The ROC curve analysis for serum Vitamin D is shown in 
Fig. 3. The area under the curve (AUC) for distinguishing 
survivors from non-survivors was 0.82 (P = 0.001) and the 
optimal cut-off level was < 25 ng/mL, with 75% specificity 
and 72% sensitivity (Table 3).
The effect of vitamin D deficiency on the risk 
of mortality
The probability of death in patients with vitamin D defi-
ciency [defined as 25(OH)D concentration < 25 ng/mL] 
was 34.6% compared with 6.4% in patients with sufficient 
vitamin D levels (P = 0.003). Logistic regression analysis 
revealed that the odds of death was significantly higher in 
vitamin D deficient patients (< 25 ng/mL) in comparison 
with discharged patients in both unadjusted (OR = 7.77, 
P = 0.005) and adjusted models (OR = 6.84, P = 0.01). Also, 
by considering death as the “event” and length of hospi-
talization as “event time”, cox regression analysis was per-
formed to evaluate the effect of Vitamin D deficiency on 
the hazard rate of death in COVID-19 patients. In adjusted 
as well as unadjusted cox models, vitamin D deficient sta-
tus increased the hazard of death (HR = 4.15, P = 0.04) 
(Table 4). Figure 4 indicates the higher risk of death in vita-
min D deficient patients during hospitalization.
Discussion
To the best of our knowledge, this is the first study to assess 
the possible association between clinical features, extent of 
lung involvement and outcome of COVID-19 with patients’ 
serum 25(OH)D concentration. The results of the present 
study showed that lower concentrations of serum 25(OH)
D are significantly associated with greater extent of lung 
Fig. 1  Log minus log of hazard function. The evaluation of the 
assumption of proportionality of hazards in cox survival models. The 
parallel log minus log functions in 25(OH)D deficiency groups and 
Schoenfeld residues analysis (chi-square = 8.02, DF = 4, P = 0.10) 
indicates that comparing hazard of death in two groups does not 
depend on time and the proportionality assumption is hold in cox 
regression
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Table 1  Comparing patient’s 
baseline characteristics, 
comorbidity factors, laboratory, 





N = 61 (83.6%)
Death
N = 12 (16.4%)
P
Age 55.18 ± 14.98 54.92 ± 15.31 56.50 ± 13.71 0.74
Sex 0.12
 Male 47 (64.4) 37 (60.7) 10 (83.3)
 Female 26 (35.6) 24 (39.3) 2 (16.7)
Signs and symptoms
 Fever 43 (58.9) 36 (59.0) 7 (58.3) 0.97
 Cough 50 (68.5) 43 (70.5) 7 (58.3) 0.50
 Sore throat 7 (9.6) 7 (11.5) 0 (0) 0.59
 Dyspnea 47 (64.4) 40 (65.6) 7 (58.3) 0.74
 Chilling 13 (17.8) 12 (19.7) 1 (8.3) 0.68
 Headache 7 (9.6) 7 (11.5) 0 (0) 0.59
 Myalgia 18 (24.7) 16 (26.2) 2 (16.7) 0.72
 Nausea 7 (9.6) 6 (9.8) 1 (8.3) 0.99
 Abdominal pain 7 (9.6) 6 (9.8) 1 (8.3) 0.99
 Diarrhea 6 (8.2) 5 (8.2) 1 (8.3) 0.61
Comorbidity factors
 Asthma/COPD 7 (9.6) 6 (9.8) 1 (8.3) 0.99
 Diabetes mellitus 11 (15.1) 10 (16.4) 1 (8.3) 0.68
 Ischemic heart disease 13 (17.8) 10 (16.4) 3 (25.0) 0.44
 Hypertension 18 (24.7) 17 (27.9) 1 (8.3) 0.27
 Chronic kidney disease 16 (21.9) 9 (14.8) 7 (58.3) 0.003
 Liver disease 1 (1.4) 1 (1.6) 0 (0) 0.99
 Immune system disorders 10 (13.7) 5 (8.2) 5 (41.7) 0.008
 Comorbidity* 42 (57.5) 33 (54.1) 9 (75.0) 0.18
Oxygen saturation 90 (86.5–93) 90 (86.5–93) 88 (85.5–90) 0.11
Hospitalization (day) 10 (7–17) 10 (7–16) 14 (9.3–19) 0.22
Laboratory findings
 25(OH) D 35.19 ± 19.05 38.41 ± 18.51 13.83 ± 12.53 < 0.001
 Ca 8.94 ± 0.68 8.50 ± 0.72 8.71 ± 0.62 0.95
 P 3.65 ± 0.62 3.58 ± 0.58 3.93 ± 0.81 0.33
 Mg 2.07 ± 0.66 2.11 ± 0.70 1.84 ± 0.18 0.40
CT scan involvement pattern 0.26
 Ground glass opacities 47 (64.4) 40 (65.6) 7 (58.3)
 Consolidation 13 (17.8) 9 (14.8) 4 (33.3)
 Reticular 8 (11.0) 8 (13.1) 0 (0)
 Mixed 5 (6.8) 4 (6.6) 1 (8.3)
Involvement distribution 0.95
 Peripheral 53 (72.6) 44 (72.1) 9 (75.0)
 Central 8 (11.0) 7 (11.5) 1 (8.3)
 Both 12 (16.4) 10 (16.4) 2 (16.7)
Zone involvement score
 Upper 2 (1–3) 2 (0–3) 3.5 (2.2–5) 0.005
 Middle 3 (2–6) 3 (2–4) 6 (5–6.8) < 0.001
 Lower 4 (2–6) 3 (2–5) 7 (4.3–8) < 0.001
 Total lung 8 (5–15) 8 (5–11) 16 (13.5–18.8) < 0.001
CT-scan findings
 Airway thickening 57 (78.1) 46 (75.4) 11 (91.7) 0.28
 Crazy paving 7 (9.6) 6 (9.8) 1 (8.3) 0.99
 Reverse halo 1 (1.4) 1 (1.6) 0 (0) 0.99
 Lymph node 4 (5.5) 3 (4.9) 1 (8.3) 0.52
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involvement and poorer outcome in patients with COVID-
19. Moreover, based on both unadjusted and adjusted mod-
els of logistic regression analysis, the odds of death were 
significantly higher in vitamin D deficient patients (25(OH)
D < 25 ng/mL).
In a meta-analysis by Martineau et al., it was shown 
that vitamin D supplementation significantly decreases the 
chance of experiencing at least one acute respiratory tract 
infection. In particular, vitamin D supplementation showed 
a stronger protective effect in patients with a serum 25(OH)
D level of less than 10 ng/ mL [18].
A recent study, conducted across 20 European countries, 
aimed to investigate the association of serum vitamin D level 
with COVID-19-related morbidity and mortality. The results 
of this study showed that the mean level of serum vitamin 
D in each country has a significant relationship with the 
number of infected cases as well as the mortality rate of 
that specific country [19, 20]. Patients who are more likely 
to be vitamin D deficient such as the elderly and people 
of the black and minority ethnic (BAME) heritage have 
been shown to be prone to severe COVID-19. Nevertheless, 
infants and children experience milder forms of the disease 
despite the fact that they are at an increased risk of vitamin 
D deficiency compared with adults [10]. In this study, we 
aimed to report serum 25(OH)D levels in all inpatients and 
outpatients with COVID-19 and during different stages of 
the disease. Although some trials are in progress, thus far, no 
study has investigated the effect of vitamin D on the course 
and outcome of COVID-19, Hence, a practical guideline 
advising the use of vitamin D supplements in the general 
population or in critically ill patients with COVID-19 has 
not been introduced yet. Based on a previous study that was 
conducted on patients with respiratory disease, Ebadi et al. 
suggested a treatment plan for vitamin D supplementation, 
which could quickly and safely increase serum 25(OH)D 
levels [21]. They suggested that patients with low circulat-
ing levels of vitamin D (below 50 nmol/L) should be offered 
50,000 IU of vitamin D supplementation twice weekly at 
diagnosis. Then, following the initial dose (100,000 IU), 
patients should continue with a dosage of 50,000 IU once a 
week for the second and third week of treatment. Patients at 
higher risk of developing COVID-19 infection such as those 
with diabetes, transplant recipients [22] or the elderly could 
consider taking a daily oral dose of 1000 IU for a few weeks 
to raise their serum level of vitamin D above 30–50 ng/ml. 
Indeed for therapeutic intention, larger doses are probably 
required.
Recently, a growing body of literature has focused on the 
advantages of calcifediol compared with cholecalciferol for 
vitamin D supplementation. Unlike calcifediol, cholecalcif-
erol guarantees an exact dosage of vitamin D and has phar-
macokinetic properties that allow for daily or even weekly 
Table 1  (continued) Variables Total
N = 73
Discharged
N = 61 (83.6%)
Death
N = 12 (16.4%)
P
 Dilated vessel 49 (67.1) 37 (60.7) 12 (100) 0.006
 Airway dilatation 34 (46.4) 25 (41.0) 9 (75.0) 0.05
 Air bronchogram 21 (28.8) 14 (23.0) 7 (58.3) 0.03
 Septal thickening 10 (13.7) 8 (13.1) 2 (16.7) 0.67
Data are represented as mean ± SD, median (Q1–Q3), and frequency (percent)
Mean and median differences were tested using independent T test and Mann–Whitney U test, respectively. 
The distributions of categorical data were compared by chi-square test (with exact P value)
*At least one of the comorbidity features is positive
Table 2  Multivariate linear regression results in the association of 25(OH) D concentration and lung involvement scores
*Unadjusted multivariate model
**Adjusted multivariate model
Variables Upper Zone Middle zone Lower zone Total
β (SE) P β (SE) P β (SE) P β (SE) P
25(OH) D* − 0.04 (0.011) 0.003 − 0.04 (0.012) 0.003 − 0.03 (0.014) 0.02 − 0.11 (0.034) 0.003
Age 0.02 (0.014) 0.29 0.03 (0.015) 0.038 0.04 (0.018) 0.04 0.08 (0.042) 0.05
Sex (male) 0.79 (0.44) 0.08 0.67 (0.47) 0.16 − 0.55 (0.56) 0.33 0.91 (1.34) 0.50
Comorbidity (yes) 0.78 (0.42) 0.07 1.09 (0.45) 0.018 0.68 (0.54) 0.21 2.55 (1.28) 0.05
25(OH) D** − 0.03 (0.011) 0.003 − 0.03 (0.012) 0.005 − 0.04 (0.014) 0.01 − 0.10 (0.034) 0.004
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or monthly administration of vitamin D in equivalent doses, 
facilitating adherence to treatment. Furthermore, regard-
less of the pattern of administration, cholecalciferol is more 
likely to achieve serum levels of 30–50 ng/mL of 25(OH)D 
[23]. On the other hand, compared to oral cholecalciferol, 
oral calcifediol results in a more rapid increase in serum 
25(OH)D, is more potent and has a higher rate of intesti-
nal absorption. In addition, it has a linear dose–response 
Fig. 2  a–c A 55-year-old man presented with 5-day history of fever 
and dry cough without any comorbidity [25(OH)D level was 40 ng/
mL] with initial lung computed tomography (CT) involvement score 
of eight/24. On admission, CT images showed subtle patchy ground-
glass opacities (GGO) (long arrows) predominantly in upper zones 
and reticular pattern (wide arrows) in lower zones. The patient dis-
charged after 6  days. d–f A 54-year-old man presented with 4-day 
history of fever, dry cough and dyspnea and no other comorbidity 
[25(OH)D level was 7  ng/mL]. Lung CT score involvement score 
of ninety/24. On admission, CT images showed diffuse GGO (long 
arrows) with slight consolidation change (thick head arrow) in right 
mid zone. The patient died after 19 days
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curve that can result in fairly stable levels of serum 25(OH) 
D, irrespective of baseline 25(OH)D concentration [24]. It 
seems that administering oral cholecalciferol should be pre-
ferred in the general population with COVID-19 while in 
ICU patients and in patients with intestinal malabsorption 
syndromes, calcifediol is a more appropriate alternative.
Zhao and colleagues proposed that chest CT could be a 
useful tool in assessing the severity of COVID-19 infection 
[25]. Our study showed that higher levels of 25(OH)D are 
associated with decreased amount of lung involvement on 
chest CT, possibly suggesting a milder form of disease.
Our study had some limitations such as the single center 
design and small sample size.
In conclusion, this study provides new evidence for clini-
cians and health policy makers to consider vitamin D sup-
plementation for the improvement of clinical outcome of 
patients with COVID-19. We believe that vitamin D might 
be able to protect patients against developing severe form of 
disease once infected.
Fig. 3  ROC curve analysis results to achieve predictive values of 
25(OH)D in classifying patients into dead or discharge
Table 3  ROC curve analysis results in differentiating dead and discharged patients using 25 (OH) D levels
PLR positive likelihood ratio, NLR negative likelihood ratio
Variable AUC (95% CI) P Cutoff Sensitivity Specificity PLR NLR
25(OH) D 0.82 (0.68–0.95) 0.001 < 25 0.75 0.72 2.68 0.34
Table 4  The hazard and odds 
of death affected by 25 (OH) 
D deficiencies in patients with 
COVID-19
Model 1: crude effect, Model 2: adjusted effect
OR Odds Ratio, HR Hazard Ratio, CI Confidence interval
Models Variables Logistic model Cox model
OR (95% CI) P HR (95% CI) P
Model 1 25(OH) D deficiency 7.77 (1.87–32.17) 0.005 3.91 (1.05–14.54) 0.04
Model 2 Age 1.01 (0.96–1.06) 0.65 1.01 (0.97–1.06) 0.69
Sex (male) 2.38 (0.43–13.12) 0.32 1.31 (0.24–7.09) 0.75
Comorbidity (yes) 2.54 (0.57–11.34) 0.22 0.98 (0.22–3.51) 0.86
25(OH) D deficiency 6.84 (1.55–30.19) 0.01 4.15 (1.07–16.19) 0.04
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